Principal Financial Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-24,599
| Closed | -$945K | – | 2494 |
|
|
2023
Q2 | $945K | Buy |
24,599
+355
| +1% | +$9.12K | ﹤0.01% | 1853 |
|
|
2023
Q1 | $561K | Sell |
24,244
-311
| -1% | -$7.41K | ﹤0.01% | 1947 |
|
|
2022
Q4 | $643K | Buy |
24,555
+12,401
| +102% | +$275K | ﹤0.01% | 1923 |
|
|
2022
Q3 | $239K | Sell |
12,154
-9,358
| -44% | -$188K | ﹤0.01% | 2153 |
|
|
2022
Q2 | $376K | Buy |
+21,512
| New | +$338K | ﹤0.01% | 2127 |
|
|
2020
Q3 | – | Sell |
-2,096
| Closed | -$24K | – | 2368 |
|
|
2020
Q2 | $24K | Buy |
+2,096
| New | +$28.9K | ﹤0.01% | 2304 |
|
|
2019
Q4 | – | Sell |
-2,099
| Closed | -$11K | – | 2299 |
|
|
2019
Q3 | $11K | Buy |
+2,099
| New | +$13.9K | ﹤0.01% | 2242 |
|
|
2018
Q4 | – | Sell |
-4,747
| Closed | -$174K | – | 2332 |
|
|
2018
Q3 | $174K | Buy |
4,747
+2,476
| +109% | +$79.5K | ﹤0.01% | 2189 |
|
|
2018
Q2 | $79K | Sell |
2,271
-411
| -15% | -$15.8K | ﹤0.01% | 2231 |
|
|
2018
Q1 | $125K | Buy |
2,682
+243
| +10% | +$8.89K | ﹤0.01% | 2143 |
|
|
2017
Q4 | $91K | Buy |
+2,439
| New | +$106K | ﹤0.01% | 2194 |
|
Principal Financial Group's KDNY Position: Q3 2023 in Review
Principal Financial Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 24,599 shares — an estimated $945K sold.
Principal Financial Group first reported a position in KDNY in Q4 2017 and held it in 11 quarters. The position peaked at $945K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Principal Financial Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Principal Financial Group sold 24,599 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $945K.
- Principal Financial Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 11 quarters.
- Principal Financial Group's Chinook Therapeutics, Inc. Common Stock position peaked at $945K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Principal Financial Group's 13F filing for Q3 2023, filed 2 Nov 2023.